-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
While the treatment of iatrogenic and HIV-related Kaposi's sarcoma is well established and is primarily based on restoring immune function, the treatment of classical and endemic Kaposi's sarcoma is not well established
.
Chemotherapy or interferon alfa are used in patients with extensive cutaneous or visceral Kaposi's sarcoma, but may be poorly tolerated and fewer patients achieve long-term remission
The aim of this study was to evaluate the therapeutic activity of pembrolizumab in classical and endemic Kaposi's sarcoma requiring systemic therapy
.
This is a multicenter, single-arm, proof-of-concept Phase 2 clinical trial enrolling patients 18 years of age and older with histologically confirmed classic or endemic Kaposi's sarcoma requiring systemic therapy
.
Subjects received pembrolizumab (200 mg) every 3 weeks for 6 months (8 cycles) or experienced severe toxicity
Treatment response in all patients
Treatment response in all patientsBetween July 2, 2018, and December 16, 2019, we screened a total of 30 patients, of whom 17 (8 classic Kaposi's sarcoma, 9 endemic Kaposi's sarcoma) were eligible for inclusion
.
After a median follow-up of 20.
20.
HLA-B HED levels in patients with and without remission
HLA-B HED levels in patients with and without remissionTreatment-related adverse events occurred in 13 (76%) patients, including two grade 3 adverse events (1 acute cardiac decompensation and 1 granulomatous reaction)
.
Two (12%) patients discontinued study treatment early due to grade 3 acute reversible cardiac decompensation and grade 2 pancreatitis, and one additional patient had a grade 3 granulomatous reaction in the mediastinal lymph nodes requiring steroids and methotrexate
This prospective study is the first to evaluate the efficacy of PD-1 blockade in classical or endemic Kaposi's sarcoma
.
The results of this study showed that pembrolizumab exhibited promising antitumor activity in patients with this type of Kaposi's sarcoma, with a good safety profile
Pembrolizumab has shown promising antitumor activity in such Kaposi sarcoma patients, and with good safety pembrolizumab has shown promising antitumor activity in such Kaposi sarcoma patients, and good security
Original source:
Original source:Julie Delyon, et al.
leave a message here
